Longevity & AgingBioAge Launches Phase 2 Trial Testing Inflammaging Drug for Cardiovascular Risk
BioAge Labs has dosed the first participant in QUELL-CV, a Phase 2 trial testing BGE-102, an oral drug that blocks the NLRP3 inflammasome — a key driver of chronic low-grade inflammation linked to aging. Unlike most drug programs, BioAge discovered this target by analyzing human longevity datasets, identifying what separates people who age well from those who don't. The trial uses high-sensitivity C-reactive protein (hsCRP) as its primary biomarker to measure anti-inflammatory effects and establish dosing, with a focus on adults carrying elevated cardiovascular risk. If successful, this approach could validate inflammaging as a druggable target across multiple age-related diseases, not just heart disease — a potential milestone for longevity medicine.
